Patents Assigned to Tanabe Pharma Corporation
-
Patent number: 9555025Abstract: Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene·3/2 hydrate, 3 to 7% by weight of a separation inhibitor, 15 to 50% by weight of a hydrocarbon gel, a pH controller and 0.05 to 0.4% by weight of an antioxidant, has excellent drug stability and excellent drug dispersibility. In the present ointment, polyoxyethylene (196) polyoxypropylene (67) glycol is preferred as the separation inhibitor, diisopropanolamine is preferred as the pH controller, and dibutylhydroxytoluene is preferred as the antioxidant.Type: GrantFiled: March 28, 2012Date of Patent: January 31, 2017Assignees: Maruho Co., Ltd., Mitsubishi Tanabe Pharma CorporationInventors: Tomoki Sakaguchi, Hidetoshi Emi
-
Publication number: 20170014419Abstract: Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.Type: ApplicationFiled: April 3, 2015Publication date: January 19, 2017Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kenji KANGAWA, Hiroshi HOSODA, Takashi NOJIRI
-
Patent number: 9546155Abstract: The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.Type: GrantFiled: June 14, 2013Date of Patent: January 17, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kunio Saruta, Norimitsu Hayashi, Osamu Sakurai, Hiroaki Sawamoto, Eri Ooboki
-
Patent number: 9540360Abstract: Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.Type: GrantFiled: February 12, 2015Date of Patent: January 10, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Yasuyuki Tsuzuki, Daisuke Sawamoto, Toshiaki Sakamoto, Taku Kato, Yasuki Niwa, Nobumasa Awai
-
Patent number: 9533983Abstract: The present invention relates to a novel antiplatelet agent and a novel compound which is an active ingredient for the agent. The present invention provides the antiplatelet agent comprising a compound represented by the formula I: wherein, X is N, or CR1d, Xb1-Xb5 are the same or different, and are nitrogen or carbon, R1a-R1d are the same or different, and are hydrogen, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted alkylthio, an alkenyl, a cycloalkyl, a halogen, cyano, or hydroxyl or optionally substituted by 1 or 2 alkylamino, R2 is an optionally substituted aryl or an optionally substituted heteroaryl, R3 is an optionally substituted aryl or an optionally substituted heteroaryl, or pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: February 25, 2014Date of Patent: January 3, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hiroshi Sato, Kazutoshi Yokoyama, Kazushi Sato
-
Publication number: 20160376289Abstract: The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom, X3 is a nitrogen atom, or CR2, X4 is a nitrogen atom, or CR3, X5 is a sulfur atom, or —CH?CH—, Z1 is an oxygen atom, —C(R6)(R7)—, —NH—, —C(R6)(R7)—NH—, —NH—C(R6)(R7)—, —C(R6)(R7)—O—, —O—C(R6)(R7)—, or a single bond, one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: April 22, 2015Publication date: December 29, 2016Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Masahiro OKUYAMA, Kenji FUKUNAGA, Kenji USUI, Norimitsu HAYASHI, Daisuke IIJIMA, Hideki HORIUCHI, Noriaki ITAGAKI
-
Patent number: 9527859Abstract: The present invention relates to novel amidopyridine derivatives. More specifically, the present invention provides a medicinal agent which is useful as a prophylactic or therapeutic agent for diseases based on the production of cytokines from T cells, comprising as the active ingredient an amidopyridine derivative or a pharmacologically acceptable salt thereof. Provided are an amidopyridine derivative of the following general formula (I): wherein each symbol has the same meaning as defined in the description, or a pharmacologically acceptable salt thereof.Type: GrantFiled: April 12, 2013Date of Patent: December 27, 2016Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Masayuki Watanabe, Hiroyuki Furukawa, Maiko Hamada, Naoto Fujie, Hiroyuki Ushio, Tooru Takashima
-
Publication number: 20160362385Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.Type: ApplicationFiled: July 8, 2016Publication date: December 15, 2016Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Tomoyuki OKABE, Takeshi HAMADA, Kaori TOMIKAWA, Yukie OKAMOTO, Toru IIJIMA, Hidenori AKATSUKA, Kenichi TOYAMA, Atsushi MORODA, Yoshihiro SUGIURA
-
Patent number: 9487488Abstract: The present invention provides novel sulfonamide compounds having TRPM8 antagonistic activity which are useful as medicaments. Specifically, the present invention provides a sulfonamide compound of the formula (I): wherein Ring A is the following formula (i), (ii), or (ix): R4 is optionally substituted alkyl, X1 and X2 are each independently tetrazolyl, tetrazolinonyl, optionally substituted triazolyl, triazolinonyl, oxadiazolonyl, optionally substituted alkanoylaminomethyl, or optionally substituted alkylsulfonylaminomethyl, or R4 and X2 combine with each other at their terminals together with the adjacent benzene to form indazolinonyl or benzoisoxazolonyl, and the other symbols are the same as described in the specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 13, 2013Date of Patent: November 8, 2016Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Taku Kato, Toshiaki Sakamoto, Akira Kubo, Daisuke Sawamoto
-
Publication number: 20160272614Abstract: This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 22, 2016Publication date: September 22, 2016Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Osamu SAKURAI, Kunio SARUTA, Norimitsu HAYASHI, Takashi GOI, Kenji MOROKUMA, Hidekazu TSUJISHIMA, Hiroaki SAWAMOTO, Hiroaki SHITAMA, Ritsuo IMASHIRO
-
Publication number: 20160244517Abstract: Provided is a T cell activation inhibitor containing an RGM inhibiting substance such as an anti-RGM neutralizing antibody and the like as an active ingredient. The T cell activation inhibitor is useful as a pharmaceutical composition for the prophylaxis or treatment of autoimmune diseases such as multiple sclerosis and the like, and other diseases caused by T cell activation. In addition, a T cell activation inhibiting substance can be screened for by contacting a test substance with RGM and selecting a test substance that lowers the activity level of RGM.Type: ApplicationFiled: May 9, 2016Publication date: August 25, 2016Applicant: Mitsubishi Tanabe Pharma CorporationInventors: Toshihide YAMASHITA, Takekazu KUBO
-
Publication number: 20160228375Abstract: The present invention is directed to a tablet containing a 1-(?-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound in high drug loading, in particular, containing the compound ranging from 30 to 95% by weight of tablet and pharmaceutically acceptable additives.Type: ApplicationFiled: April 20, 2016Publication date: August 11, 2016Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Masaaki SUGIMOTO, Hajime KINOSHITA, Takayuki TOKUDA
-
Patent number: 9409874Abstract: The present invention provides an industrially advantageous method for producing a 1,4-benzoxazine compound useful as a medicine while avoiding safety and health risks. Specifically, the present invention provides a method for producing a 1,4-benzoxazine compound [A], which comprises the three steps in the following scheme, namely, a step of converting the amino group at 7-position in a compound [a] into a dimesylamino group, a step of coupling a compound [b] with a boronic acid compound, and a step of converting the 7-position in a compound [c] into a monomesylamino group. In the above scheme, Ms is a methanesulfonyl group, and each of R? and R? is a hydrogen atom etc.Type: GrantFiled: August 8, 2013Date of Patent: August 9, 2016Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Tomoyuki Okabe, Takeshi Hamada, Kaori Tomikawa, Yukie Okamoto, Toru Iijima, Hidenori Akatsuka, Kenichi Toyama, Atsushi Moroda, Yoshihiro Sugiura
-
Publication number: 20160200679Abstract: The present invention provides novel crystal forms of arylalkylamine compounds. Specifically, the novel crystal forms of 4-(3S-(1R-(1-naphthyl)ethylamino)pyrrolidin-1-yl)phenylacetic acid have excellent stability and therefore are useful as pharmaceutical ingredients. The present invention also provides industrially advantageous processes for producing the arylalkylamine compounds.Type: ApplicationFiled: September 5, 2014Publication date: July 14, 2016Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hiroshi MIYAZAKI, Takao KOMASAKA, Joji TSURUMOTO, Takeshi UEMURA, Yuuji MORITA
-
Publication number: 20160193217Abstract: The present invention provides a therapeutic agent or prophylactic agent for an ophthalmic disease caused by ocular angiogenesis, which contains a morpholine compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is a hydrogen atom and the like, or a pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: July 24, 2014Publication date: July 7, 2016Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventor: Hidemitsu HIGASHI
-
Publication number: 20160145220Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R1 is a cycloalkyl group and the like, R22 is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is —O— and the like, and R3 to R6 are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.Type: ApplicationFiled: January 12, 2016Publication date: May 26, 2016Applicants: MITSUBISHI TANABE PHARMA CORPORATION, SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.Inventors: Toru IIJIMA, Hiroshi SUGAMA, Takayuki KAWAGUCHI, Jingkang SHEN, Guangxin XIA, Jianshu XIE, Miki HIRAI
-
Patent number: 9334323Abstract: Provided is a T cell activation inhibitor containing an RGM inhibiting substance such as an anti-RGM neutralizing antibody and the like as an active ingredient. The T cell activation inhibitor is useful as a pharmaceutical composition for the prophylaxis or treatment of autoimmune diseases such as multiple sclerosis and the like, and other diseases caused by T cell activation. In addition, a T cell activation inhibiting substance can be screened for by contacting a test substance with RGM and selecting a test substance that lowers the activity level of RGM.Type: GrantFiled: December 8, 2010Date of Patent: May 10, 2016Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Toshihide Yamashita, Takekazu Kubo
-
Publication number: 20160108078Abstract: A compound of the formula: wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring or an optionally substituted unsaturated fused heterobicyclic ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, and Ring B are independently an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; X is a carbon atom or a nitrogen atom; Y is —(CH2)n— (n is 1 or 2); or a pharmaceutically acceptable salt thereof, or a prodrug thereof.Type: ApplicationFiled: December 28, 2015Publication date: April 21, 2016Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Sumihiro NOMURA, Eiji KAWANISHI, Kiichiro UETA
-
Patent number: 9302996Abstract: This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 16, 2011Date of Patent: April 5, 2016Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Osamu Sakurai, Kunio Saruta, Norimitsu Hayashi, Takashi Goi, Kenji Morokuma, Hidekazu Tsujishima, Hiroaki Sawamoto, Hiroaki Shitama, Ritsuo Imashiro
-
Patent number: 9278944Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R1 is a cycloalkyl group and the like, R22 is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is —O— and the like, and R3 to R6 are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.Type: GrantFiled: March 15, 2012Date of Patent: March 8, 2016Assignees: MITSUBISHI TANABE PHARMA CORPORATION, SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.Inventors: Toru Iijima, Hiroshi Sugama, Takayuki Kawaguchi, Jingkang Shen, Guangxin Xia, Jianshu Xie, Miki Hirai